However, in clinical trials, selective cyclooxygenase-2 (COX-2) inhibitor drug therapy proved to be ineffective for treating AD [284, 358], and protecting individuals with MCI from progressing toward AD [284]. Here, PTGS2 is linked to Alzheimer disease.